CN102574920A - 用依帕珠单抗治疗自体免疫和炎性疾病 - Google Patents

用依帕珠单抗治疗自体免疫和炎性疾病 Download PDF

Info

Publication number
CN102574920A
CN102574920A CN2010800412158A CN201080041215A CN102574920A CN 102574920 A CN102574920 A CN 102574920A CN 2010800412158 A CN2010800412158 A CN 2010800412158A CN 201080041215 A CN201080041215 A CN 201080041215A CN 102574920 A CN102574920 A CN 102574920A
Authority
CN
China
Prior art keywords
epratuzumab
treatment
week
present
inflammatory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800412158A
Other languages
English (en)
Chinese (zh)
Inventor
A-M·诺沃特尼-巴里
R·赫尔赫文
G·L·帕克
V·A·霍斯金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma SA
Original Assignee
UCB Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Pharma SA filed Critical UCB Pharma SA
Publication of CN102574920A publication Critical patent/CN102574920A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800412158A 2009-09-18 2010-08-26 用依帕珠单抗治疗自体免疫和炎性疾病 Pending CN102574920A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24379709P 2009-09-18 2009-09-18
US61/243,797 2009-09-18
PCT/EP2010/005225 WO2011032633A1 (en) 2009-09-18 2010-08-26 Treatment of autoimmune and inflammatory diseases with epratuzumab

Publications (1)

Publication Number Publication Date
CN102574920A true CN102574920A (zh) 2012-07-11

Family

ID=43063209

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800412158A Pending CN102574920A (zh) 2009-09-18 2010-08-26 用依帕珠单抗治疗自体免疫和炎性疾病

Country Status (13)

Country Link
US (1) US20110070227A1 (US07981874-20110719-C00313.png)
EP (1) EP2478012B1 (US07981874-20110719-C00313.png)
JP (1) JP5816905B2 (US07981874-20110719-C00313.png)
KR (1) KR20120100914A (US07981874-20110719-C00313.png)
CN (1) CN102574920A (US07981874-20110719-C00313.png)
AU (1) AU2010294905B2 (US07981874-20110719-C00313.png)
BR (1) BR112012006035A2 (US07981874-20110719-C00313.png)
CA (1) CA2774244A1 (US07981874-20110719-C00313.png)
EA (1) EA026902B1 (US07981874-20110719-C00313.png)
ES (1) ES2608661T3 (US07981874-20110719-C00313.png)
IN (1) IN2012DN02196A (US07981874-20110719-C00313.png)
MX (1) MX341117B (US07981874-20110719-C00313.png)
WO (1) WO2011032633A1 (US07981874-20110719-C00313.png)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105102004A (zh) * 2012-10-12 2015-11-25 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗cd22抗体结合物
WO2020078453A1 (en) * 2018-10-18 2020-04-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
EP2789684B1 (en) 2008-05-23 2016-12-21 Siwa Corporation Methods and compositions for facilitating regeneration
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531812A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3954703A3 (en) 2014-05-29 2022-05-18 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
IL251210B2 (en) * 2014-09-19 2023-12-01 Siwa Corp Anti-aging antibodies for the treatment of inflammation and autoimmune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2018191718A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
CN109071675A (zh) 2016-02-19 2018-12-21 Siwa有限公司 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物
US11958900B2 (en) 2016-04-15 2024-04-16 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX2019004580A (es) 2016-10-21 2019-08-12 Amgen Inc Formulaciones farmaceuticas y metodos para prepararlas.
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
DK3544636T3 (da) 2017-02-08 2021-05-10 Adc Therapeutics Sa Pyrrolobenzodiazepin-antistof-konjugater
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
WO2019034764A1 (en) 2017-08-18 2019-02-21 Medimmune Limited CONJUGATES OF PYRROLOBENZODIAZEPINE
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101490087A (zh) * 2006-05-30 2009-07-22 健泰科生物技术公司 抗体和免疫偶联物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
AU3272695A (en) * 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
DE05075555T1 (de) * 1999-06-09 2007-02-08 Immunomedics, Inc. Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
EP2330130B1 (en) * 2002-10-17 2014-08-27 Genmab A/S Human monoclonal antibodies against CD20
WO2007103469A2 (en) * 2006-03-06 2007-09-13 Aeres Biomedical Ltd. Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8283162B2 (en) * 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101490087A (zh) * 2006-05-30 2009-07-22 健泰科生物技术公司 抗体和免疫偶联物及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANOLIK JENNIFER H ET AL.: "New treatments for SLE:cell-depleting and anti-cytokine therapies.", 《BEST PRACTICE & RESEARCH.CLINICAL RHEUMATOLOGY》 *
DORNER THOMAS ET AL: "Targeting CD22 as a strategy for treating systemic autoimmune disease.", 《THERAPEUTICS AND CLINICAL RISK MANAGEMENT》 *
THOMAS DÖRNER ET AL: "Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus", 《ARTHRITIS RESEARCH & THERAPY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105102004A (zh) * 2012-10-12 2015-11-25 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗cd22抗体结合物
CN105102004B (zh) * 2012-10-12 2019-01-25 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗cd22抗体结合物
WO2020078453A1 (en) * 2018-10-18 2020-04-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis

Also Published As

Publication number Publication date
EP2478012A1 (en) 2012-07-25
MX341117B (es) 2016-08-09
US20110070227A1 (en) 2011-03-24
JP2013505205A (ja) 2013-02-14
MX2012002907A (es) 2012-04-30
IN2012DN02196A (US07981874-20110719-C00313.png) 2015-08-21
CA2774244A1 (en) 2011-03-24
AU2010294905B2 (en) 2016-09-22
AU2010294905A1 (en) 2012-04-05
ES2608661T3 (es) 2017-04-12
JP5816905B2 (ja) 2015-11-18
EA026902B1 (ru) 2017-05-31
EA201270433A1 (ru) 2012-10-30
WO2011032633A1 (en) 2011-03-24
EP2478012B1 (en) 2016-11-09
BR112012006035A2 (pt) 2019-09-24
KR20120100914A (ko) 2012-09-12

Similar Documents

Publication Publication Date Title
CN102574920A (zh) 用依帕珠单抗治疗自体免疫和炎性疾病
TW202016148A (zh) 滋養層抗原2（trop2）特異性抗體
CN113474362B (zh) 对cd44特异性的抗体
CN113423736B (zh) 对muc18特异性的抗体
US20210284726A1 (en) Antibodies specific to folate receptor alpha
AU2010248935A1 (en) Methods and compositions for treating lupus
US20220041749A1 (en) Antibodies specific to muc18
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
EP4335872A1 (en) Bispecific antibody specifically binding to cd47 and pd-l1
Liu et al. Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain
WO2024098940A1 (zh) 双特异性抗体及其应用
CN116535509B (zh) 抗CD79b抗体、其制备方法及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1172909

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120711